| Employment |
| Company: Maastricht University |
| Recipient: An Immediate Family Member |
|
| Leadership |
| Company: Convert Pharmaceuticals SA |
| Recipient: You |
|
| Stock and Other Ownership Interests |
| Company: LivingMed Biotech |
| Recipient: An Immediate Family Member |
| Company: Bactam srl (Non medical biotech on green energy) |
| Recipient: An Immediate Family Member |
| Company: Oncoradiomics SA |
| Recipient: You |
| Company: Convert Pharmaceuticals SA |
| Recipient: You |
| Company: LivingMed Biotech sprl |
| Recipient: You |
| Company: Comunicare Solutions SA |
| Recipient: You |
| Company: Bactam srl (Non medical biotech on green energy) |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: BHV sprl |
| Recipient: You |
| Company: Institut Jules Bordet |
| Recipient: You |
| Company: Gilde Healthcare Partners |
| Recipient: You |
| Company: Roche |
| Recipient: You |
| Company: Bristol-Myers Squibb (BMS) |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: LivingMed Biotech |
| Recipient: Your Institution |
| Company: Convert Pharmaceuticals |
| Recipient: Your Institution |
| Company: Bactam srl |
| Recipient: Your Institution |
| Company: Philogen |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures. |
| Recipient: Your Institution |
| Please describe: One patent on Lymphocytes Sparing Radiotherapy (N2024889), licensed to Varian medical (1/3 of the royalties for the inventors, 2/3 for the institution) |
| Recipient: Your Institution |
| Please describe: Co-inventor of the patent "Method of training a machine learning data processing model, method of determining a hypoxia status of a neoplasm in a human or animal body and system therefore". Licensed. Patent issued on 30 April 2024 as U.S. Patent 11,972,867 |
| Recipient: Your Institution |
| Please describe: Co-inventor of a non-issued, non licensed patents on Deep Learning & Radiomics (N2024889). |
| Recipient: Your Institution |
| Please describe: Co-inventor of the patent "Prodrugs and medical uses thereof (WO2019EP64112) |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Benelux Health Ventures |
| Recipient: You |
| Company: Roche |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| Company: Institut of Cancer Research, UK |
| Recipient: You |
| Company: CRC UK Lung Cancer Center of Excellence |
| Recipient: You |
| Company: Exomnis Biotech (SAB, board member) |
| Recipient: You |
| Company: Health Innovation Ventures (CSA, board member) |
| Recipient: You |
| Company: LivingMed Biotech (CSA, board member) |
| Recipient: You |
| Company: Radiomics.bio (Oncoradiomics, CSA, board member) |
| Recipient: You |
| Company: Comunicare Solutions (CSA, board member) |
| Recipient: You |
| Company: BACTAM (Non medical biotech, CSA, board member) |
| Recipient: You |
| Company: Authorization (only until 8/22) from employer to acquire shares in Benelux Health Ventures (transaction not executed) |
| Recipient: You |
| Company: The co-CEO of Comunicare, Director of Bactam & COO of Convert Pharma is a friend of of my stepchildren |
| Recipient: You |
| Company: Principal Investigator of a Grant Awarded under the European Innovation Council (EIC) Accelerator for Convert Pharmaceuticals |
| Recipient: You |
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|